Impact of a Regional Antimicrobial Stewardship on the Length of Stay of Patients Admitted to Hospital With Pneumonia

Completed

• Conditions: Pneumonia
• Interventions: Other: antimicrobial stewardship

• Registration Number: NCT02276092
• Lead Sponsor: Royal Victoria Hospital, Canada

Brief Summary

This study evaluates the effectiveness of an antimicrobial stewardship program to reduce the length of stay of patients admitted to hospital with a diagnosis of pneumonia. The antimicrobial stewardship program will be implemented in several hospitals in Ontario, Canada. The program will identify patients with pneumonia, review their charts and make recommendations to their attending physicians about antibiotic management.

Detailed Description

Antimicrobial stewardship is defined as any activity that promotes the appropriate selection, dosing, route and duration of antibiotic therapy. Antimicrobial stewardship programs usually include pharmacists and/or doctors with expertise in infection diseases management. Prospective chart review and physician feedback is a common intervention used by antimicrobial stewardship programs to improve antibiotic utilization and patient outcomes.

Pneumonia is the most common reason for antibiotic utilization in hospitals. Significant variation in antibiotic utilization for patients with pneumonia has been repeatedly demonstrated in published studies despite the existence of best-practice treatment guidelines. Treatment variation from these guidelines has been demonstrated to result in worse outcomes such as increased mortality. Antimicrobial stewardship programs can help reduce the treatment variation from guidelines.

Despite improvements in certain outcomes, antimicrobial stewardship programs have not demonstrated any impact on the length of stay of patients admitted to hospital with pneumonia. Part of this absence of evidence may be due to poor study design and failure to recruit sufficient patients. This study will include the implementation of an antimicrobial stewardship program across many hospitals and the study design and analysis will account for the design problems of the previous studies.

Study Timeline

• Study First Submitted: 2014-10-22
• Study First Submitted QC: 2014-10-23
• Study First Posted: 2014-10-27
• Study Start: 2015-04
• Primary Completion: 2017-03
• Study Completion: 2017-04
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-24
• Last Update Posted: 2020-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1400

Inclusion Criteria

• Community-acquired pneumonia
• Immunocompetent
• Age > 18 years

Exclusion Criteria

• Admitted to an intensive care unit or high intensity unit
• Requiring invasive or non-invasive ventilation
• Life expectancy less than 3 months
• Hospitalization within the previous 3 months for at least 48 consecutive hours
• Immunocompromised defined as defined as having leukemia, lymphoma, HIV with CD4 count <=200, splenectomy or on cytotoxic chemotherapy
• Neutropenic [defined as a PMN count<=0.5x109 cells/L] from any cause
• Receiving immunosuppressants [defined as >=40 mg prednisone daily (or steroid equivalent) for >=2 weeks preceding hospitalization OR any other immunosuppressant used for systemic illness OR to prevent transplant rejection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
intervention	antimicrobial stewardship	exposure to antimicrobial stewardship intervention

Primary Outcome Measures

Name	Time	Method
Length of hospital stay	Days from time of admission to time of discharge from hospital to a maximum of 14 days from the date of admission (or time to censoring at 14 days from the date of admissionor competing event depending on which comes first)	Time (measured in days) from date of admission to one of the following potential outcomes, discharge alive, censoring at 14 days post admission, death, admission to an intensive care unit, or transfer to another hospital

Secondary Outcome Measures

Name	Time	Method
Days of antibiotic therapy	Days of antibiotic therapy for the treatment of pneumonia measured from the first day of antibiotic administered to the final day of antibiotic administered upto a maximum of 80 days	Total days of antibiotics administered for the treatment of community-acquired pneumonia
Mortality rate	30 day post-discharge from hospital	Deaths that occur post-discharge from hospital up to 30 days post-discharge
Readmission to hospital	30 day post-discharge from hospital	Readmissions to hospital that occur post-discharge from hospital up to 30 days post-discharge

Trial Locations

Locations (1)

Royal Victoria Regional Health Centre; 🇨🇦 Barrie, Ontario, Canada